好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Statin Associated Necrotizing Autoimmune Myositis and p-ANCA Vasculitis: A Rare Case Report
Neuromuscular and Clinical Neurophysiology (EMG)
P16 - Poster Session 16 (8:00 AM-9:00 AM)
11-002
To describe an unusual case report of statin associated necrotizing autoimmune myositis (NAM) and p-ANCA vasculitis within the same patient.
Statin associated necrotizing autoimmune myositis is a recognized cause of inflammatory myopathy. Historically, statin associated NAM has been described as a self-limited condition until the recognition of the immune-mediated entity of NAM. This particular myositis typically comprises roughly 15% of inflammatory myopathies, and can result in significant disability in up to 25% of patients.
NA

A 66-year-old man presented with subacute, progressive bilateral proximal extremity pain and weakness. He had been on atorvastatin 10 mg for four years. Physical exam was significant for reduced muscle strength involving his proximal muscles in the upper and lower extremities.

Initial labs were significant for an elevated creatinine kinase (CK) of 3503 U/L and markedly elevated HMG-CoA reductase Antibody (>200 units). An electromyogram and nerve conduction study demonstrated a diffuse and active irritable myopathy. Treatment with monthly IVIG 1g/kg and high dose steroids was initiated, and shortly after he developed renal injury. Muscle biopsy of the left biceps brachii revealed a necrotizing myopathy with perivascular inflammation and necrosis of medium sized vessels. P-ANCA antibody was positive and kidney biopsy showed necrosis and fibrocellular crescent formation in numerous glomeruli.

With ongoing immunosuppression, the patient has had complete remission of his vasculitis and myositis.

The patient presented with clear clinical, serological, and histopathological findings of both antibody confirmed statin associated NAM and p-ANCA vasculitis. This has never been described before in literature, and is a novel case. The potential for this clinical occurrence may increase as national statin usage continues to rise. Both may be potentially secondary to statin usage, with overlapping pathogeneses. This case may aid in early consideration of treatments for beneficial patient outcomes.
Authors/Disclosures
Chantal Bhan, DO
PRESENTER
Dr. Bhan has nothing to disclose.
Paul T. Twydell, DO, FAAN (Corewell Health) Dr. Twydell has received publishing royalties from a publication relating to health care.